Physician profile
Ora Schwope
NPI 1730303215
$2,976.01
in general payments reported to CMS, 2019-2025
26 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,541 · 2020: $85.56 · 2021: $426 · 2022: $253 · 2023: $186 · 2024: $145 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,321.96 | 2019 | |
| Hologic Sales and Service, LLC | $275.40 | 2021-2025 | Aptima |
| Mayne Pharma Commercial LLC | $245.53 | 2021-2025 | |
| Abbvie INC. | $199.72 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $189.30 | 2021-2025 | Exparel |
| Pfizer INC. | $113.58 | 2019-2025 | |
| Roche Diagnostics Corporation | $98.95 | 2019-2020 | |
| Astellas Pharma US INC | $87.43 | 2021-2023 | Veozah |
| Organon LLC | $53.43 | 2022-2025 | Nexplanon, Jada System |
| Mylan Pharmaceuticals INC. | $41.63 | 2019-2021 | |
| Myovant Sciences INC. | $34.16 | 2021-2022 | |
| Sage Therapeutics, LLC | $32.55 | 2020 | |
| Millicent US INC | $32.08 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Exeltis, USA INC. | $32.08 | 2022-2023 | Slynd |
| Avanos Medical | $30.13 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $29.03 | 2021 | |
| Merck Sharp & Dohme LLC | $28.79 | 2019-2022 | |
| Acessa Health INC. | $26.35 | 2019 | |
| Biogen, INC. | $17.38 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $17.32 | 2024 | Paragard T 380a |
| Shield Therapeutics INC | $16.64 | 2023 | Accrufer |
| Daiichi Sankyo INC. | $13.90 | 2019 | |
| Minerva Surgical, INC | $12.30 | 2019 | |
| Therapeuticsmd, INC. | $11.97 | 2019 | |
| Evofem Biosciences, INC. | $7.94 | 2025 | Solosec, Phexx, Phexxi |
| Meditrina | $6.46 | 2023-2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ora Schwope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.